The mutational burden in t-AML is similar to de novo AML, but the relative frequency of specific mutations differs significantly, e.g., mutations in the gene encoding nucleophosmin (NPM1) are not as common in t-AML as in de novo AML (Figure 2) [16,32,33]. The gene discussed is NPM1; the disease is acute myeloid leukemia.